Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scrip Asks...What Is The Current Trend For Open Innovation In Asia?

Executive Summary

Open Innovation and global partnering are becoming one of the most frequent themes of bio conferences in South Korea and elsewhere. Scrip talked to global experts at the recent Bio Korea 2018 meeting about their views on the current climate and trends for open innovation in Asia, as well as some challenges and benefits in pursuing open innovation approaches with Asian companies.

You may also be interested in...



GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation

In what appears to be the first open innovation-based partnership between leading South Korean pharma firms, GC Pharma and Yuhan have agreed to conduct joint early research on orphan drugs, capitalizing on each others' strengths. The move may herald a shift in domestic companies' views on such collaboration and a possible increase in similar tie-ups, amid their ongoing efforts to pursue innovation.

J&J Hones In On Research Alliances, Human Capital As It Expands Singapore Hub

J&J is building its broad presence in Asia Pacific with the opening of an expanded regional hub in Singapore that will pursue R&D partnership, "design-led" health solutions, and human resource development.

How Intract Is Helping Shape Microbiome-Based Therapies

Bill Lindsay, CEO of University College London spin-out Intract Pharma, tells Scrip in an interview how the firm’s novel technologies are expected to play a key role in the effective delivery of microbiome-based therapies.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC123094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel